MortonColemanMD

Oncology • New York, NY

Clinical Professor of Medicine, Cornell University-Weill Medical College

Join to view full profile

Dr. Coleman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Coleman's full profile

Already have an account?

Office
407 E 70th St
3rd Floor
New York, NY 10021
Phone+1 212-517-5900

Fax+1 212-734-9238

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1967 - 1968
Emory University School of MedicineResidency, Internal Medicine, 1963 - 1965
Virginia Commonwealth University School of MedicineClass of 1963

Certifications & Licensure

NY State Medical License 1968 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2002-2008, 2011-2013
Most Compassionate Doctor American Registry
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Start of enrollment: 2013 Dec 01
Completed
Phase 2
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
No longer available
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Start of enrollment: 2017 Feb 15
Completed
Phase 1
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Start of enrollment: 2017 Jun 07
Terminated
Phase 3
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma Start of enrollment: 2019 Feb 19
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE...
Paolo Strati, Richy Agajanian, Izidore S Lossos, Morton Coleman, Robert Kridel
British Journal of Haematology. 2024-12-12
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.
Paolo Strati, Rebecca Champion, Morton Coleman, Sonali M Smith, Parameswaran Venugopal
British Journal of Haematology. 2024-12-01
2 citations
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu
Ejhaem. 2023-02-01

Journal Articles

Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell Lymphoma
Jia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
Oral Lymphomatoid Papulosis Type C: A Diagnostic Pitfall, Often Confused with T-cell Lymphoma☆
Jennifer P Toyohara, Morton Coleman, Ziv Schwartz, ScienceDirect

Abstracts/Posters

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma
Morton Coleman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not ...
Morton Coleman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma
Morton Coleman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis
Morton Coleman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).
2019 ASCO Annual Meeting - 6/1/2019
Chairman, Lymphoma & Myeloma 2013: An International Congress on Hematologic Malignancies
Waldorf-Astoria Hotel, New York, New York - 10/24/2013
Moderator, Expert Reviews in Hematology 2014: 20th Annual Network of Oncology Clinicians & Researchers (NOCR) Meeting
Imedex, Las Vegas, Nevada - 2/27/2014

Press Mentions

$Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)$
Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)November 3rd, 2020
Dr. Furman on Acalabrutinib Monotherapy in CLLFebruary 10th, 2020
42-Month Follow-up Data of Acalabrutinib Monotherapy in R/R CLLDecember 9th, 2019
Join now to see all